Silexion Therapeutics Corp filed a Form D with the Securities and Exchange Commission on 2025-08-11.
Silexion Therapeutics Corp filed a Form D notice of an exempt securities offering with the SEC on August 11, 2025. The filing reports $3.60M sold. Its industry group is Biotechnology. It names Ilan Hadar (Executive Officer, Director), Mirit Horenshtein-Hadar (Executive Officer), Ruth Alon (Director) (SEC Form D, August 11, 2025).
Is this your company?
Sell to companies like Silexion Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-11 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Silexion Therapeutics Corp.
Free to see. No signup.
More on the people and the money behind Silexion Therapeutics Corp, from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Silexion Therapeutics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Silexion Therapeutics Corp raises, hires or launches. No email unless you switch it on.
Watch Silexion Therapeutics Corp →Get the full cited report on Silexion Therapeutics Corp
What the filing shows about Silexion Therapeutics Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Silexion Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Silexion Therapeutics Corp's address as 12 Abba Hillel Road, Ramat Gan, L3 5250606.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Silexion Therapeutics Corp See pricing
Silexion Therapeutics Corp is a registered filer with the SEC (CIK 2022416) and has filed since 2025-08-11. 1 filing is on record, the latest on 2025-08-11.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Silexion Therapeutics Corp's Form D of 2025-08-11 names Ilan Hadar, Mirit Horenshtein-Hadar, Ruth Alon and 6 more as its officers, directors or promoters.
Its new offerings report $3.60M sold across 1 offering, as its own filings state.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Silexion Therapeutics Corp expects to use any proceeds from the future exercise of the new warrants for general corporate purposes. No proceeds are expected to be paid to executive officers, directors, or promoters.
Checked away from the filing. What is below does not come from the record on sec.gov.
Silexion Therapeutics is a clinical-stage biopharmaceutical company developing innovative RNAi treatments for pancreatic cancer, led by SIL204 in a Phase 2/3 clinical program.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Ilan Hadar is named as Executive Officer and Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Mirit Horenshtein-Hadar is named as Executive Officer on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Ruth Alon is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Ilan Levin is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Avner Lushi is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Shlomo Noy is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Amnon Peled is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Dror Abramov is named as Director on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
Mitchell Shirvan is named as Executive Officer on the Form D that Silexion Therapeutics Corp filed with the SEC on 11 August 2025, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2025-08-11 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Silexion Therapeutics Corp
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Silexion Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silexion Therapeutics Corp covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Silexion Therapeutics CorpYou get an alert in MentionFox the next time this company shows up.
If you're behind Silexion Therapeutics Corp: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-01 (silexion.com).
Each opens in a new tab, filled in for Silexion Therapeutics Corp. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/silexion-therapeutics-corp-form-d-25000001